Ani Pharmaceutic SEC Filings

ANI Pharmaceuticals director reports stock sale and charitable gift. A company director filed a Form 4 showing the sale of 8,643 shares of ANI Pharmaceuticals Inc. common stock on 11/13/2025 at a weighted average price of $86.88 per share, leaving 61,405 shares beneficially owned immediately after the sale. The same day, the director made a bona fide gift of 3,000 shares of common stock to a donor-advised fund for charitable purposes, with no beneficial ownership or control retained over the donated shares, reducing the director’s holdings to 58,405 shares held directly.

ANI Pharmaceuticals (ANIP) reported insider transactions by its SVP – Corp. Dev. & Strategy. On 11/12/2025, the reporting person sold 14,642 shares of common stock at a weighted average price of $89.07, with trades ranging from $89.00 to $89.50. On 11/13/2025, an additional 94 shares were sold at $88.00.

Following these transactions, the filer beneficially owned 73,615 shares directly and 158,490 shares indirectly through Chali Properties LLC, over which the reporting person holds voting and dispositive power.

ANI Pharmaceuticals furnished an updated investor presentation to the investor relations section of its website and attached it as Exhibit 99.1. The presentation is dated November 2025 and may be used in meetings with investors, analysts, and others.

The materials were provided under Items 2.02 and 7.01 and are expressly designated as furnished, not filed, under the Exchange Act, and are not subject to Section 18 liabilities or incorporated into other filings unless specifically referenced.

ANI Pharmaceuticals (ANIP) reported strong Q3 2025 results. Net revenues were $227.8 million, up from $148.3 million a year ago. Net income was $26.6 million versus a loss of $24.2 million, and diluted EPS was $1.13. Operating income reached $36.2 million, helped by higher sales in Rare Disease and Brands, especially Cortrophin Gel and the addition of ILUVIEN and YUTIQ.

Year-to-date, net revenues were $636.3 million versus $423.8 million. Operating cash flow was $154.9 million. Cash and cash equivalents were $262.6 million as of September 30, 2025. The company completed the Alimera acquisition in 2024 and in March 2025 expanded ILUVIEN’s U.S. label to include NIU-PS, shifting U.S. promotion from YUTIQ to ILUVIEN. As of October 31, 2025, there were 22,458,168 shares of common stock outstanding.

ANI Pharmaceuticals (ANIP) reported an insider transaction on a Form 4. Senior Vice President, General Counsel & Secretary Meredith W. Cook sold 400 shares of common stock on 10/13/2025 at $90.09 per share under a Rule 10b5-1 trading plan adopted on September 17, 2024.

Following the sale, Cook beneficially owns 75,674 shares, held directly. This filing reflects routine insider activity disclosed for transparency.

ANI Pharmaceuticals officer Krista Davis reported a sale of 1,000 shares of ANIP common stock on 09/19/2025 at a price of $98.04 per share. The sale was executed under a Rule 10b5-1 trading plan adopted August 23, 2024. After the transaction, the reporting person beneficially owns 60,186 shares, held directly. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and records the transaction as a routine, preplanned disposition under the company insider trading plan.

Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals (ANIP), reported a tax-withholding disposition tied to the vesting of restricted stock. On 09/12/2025 she disposed of 1,710 shares of common stock at a price of $97.71 per share; following the transaction she beneficially owns 61,186 shares. The filing notes those shares were withheld to satisfy tax obligations related to the vesting of 4,108 previously granted restricted shares.

The Form 4 was signed via attorney-in-fact on 09/15/2025. This is a routine, non-derivative withholding to cover taxes on vested restricted stock rather than an open-market sale or a new transfer of ownership.